Declining Stock and Decent Financials: Is The Market Wrong About Cross Country Healthcare, Inc. (NASDAQ:CCRN)?
Should You Consider Selling Cross Country Healthcare (CCRN)?
Cross Country Healthcare, Inc. (NASDAQ:CCRN) Shares Could Be 38% Below Their Intrinsic Value Estimate
Cross Country Named Most Loved Workplace for 2024
Cross Country Healthcare Issues Non-Binding Press Release
Cross Country Healthcare to Attend the Morgan Stanley 22nd Annual Global Healthcare Conference and the 17th Annual Barrington Research Virtual Fall Investment Conference
There May Be Reason For Hope In Cross Country Healthcare's (NASDAQ:CCRN) Disappointing Earnings
Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $19
Buy Rating Affirmed for Cross Country Healthcare Amidst Resilient Q2 Performance and Strategic Growth Potential
Results: Cross Country Healthcare, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Cross Country Healthcare Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Cross Country Healthcare | 10-Q: Q2 2024 Earnings Report
There's No Escaping Cross Country Healthcare, Inc.'s (NASDAQ:CCRN) Muted Earnings Despite A 34% Share Price Rise
Truist Adjusts Cross Country Healthcare's PT to $17 From $16, Keeps Hold Rating
Cross Country Healthcare Analyst Ratings
Benchmark Co. Maintains Cross Country Healthcare(CCRN.US) With Buy Rating, Maintains Target Price $19
Benchmark Co. analyst Bill Sutherland maintains $Cross Country Healthcare(CCRN.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success
Oppenheimer Maintains Cross Country Healthcare(CCRN.US) With Hold Rating
Oppenheimer analyst Michael Wiederhorn maintains $Cross Country Healthcare(CCRN.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 68.3% and a total average return
Cross Country Healthcare (CCRN) Receives a Rating Update From a Top Analyst
Express News | Cross Country Healthcare Inc : Truist Securities Raises Target Price to $17 From $16
JMP Securities Sticks to Its Hold Rating for Cross Country Healthcare (CCRN)